No. | Pathway name | Measured metabolites in the pathway (N) | Expected pathway proportion (P = N/673) | Expected hits in sample of 58 (P * 58) | Observed hits in the top 58 metabolites | Fold enrichment (Obs/Exp) | Impact (Sum VIP score) | Fraction of impact (VIP) explained (% of 136.0) | Suramin treatment effect (KO-Sur/KO-Sal) |
---|---|---|---|---|---|---|---|---|---|
1 | Purine metabolism | 41 | 0.061 | 3.54 | 5 | 1.41 | 27.2 | 20.0% | 4/5 Decreased |
2 | Fatty acid oxidation and synthesis | 39 | 0.057 | 3.37 | 9 | 2.67 | 16.8 | 12.4% | 9/9 Decreased |
3 | Eicosanoid and resolvin metabolism | 36 | 0.053 | 3.11 | 6 | 1.93 | 14.7 | 10.8% | 4/6 Increased |
4 | Ganglioside metabolism | 12 | 0.018 | 1.04 | 6 | 5.79 | 13.4 | 9.8% | 6/6 Increased |
5 | Phospholipid metabolism | 115 | 0.18 | 9.93 | 6 | 0.60 | 11.5 | 8.5% | 6/6 Increased |
6 | Sphingolipid metabolism | 72 | 0.105 | 6.21 | 5 | 0.80 | 11.1 | 8.2% | 3/5 Decreased |
7 | Microbiome metabolism | 33 | 0.047 | 2.85 | 3 | 1.05 | 6.7 | 4.9% | 2/3 Decreased |
8 | SAM, SAH, methionine, cysteine, glutathione metabolism | 22 | 0.032 | 1.90 | 3 | 1.58 | 6.7 | 4.9% | 3/3 Increased |
9 | Vitamin B3 (Niacin, NAD+) metabolism | 8 | 0.012 | 0.69 | 2 | 2.90 | 5.2 | 3.8% | 1/2 Increased |
10 | Glycolysis and gluconeogenesis | 18 | 0.026 | 1.55 | 2 | 1.29 | 4.2 | 3.1% | 2/2 Decreased |
11 | Cholesterol, cortisol, non-gonadal steroid metabolism | 29 | 0.042 | 2.50 | 2 | 0.80 | 3.2 | 2.4% | 2/2 Increased |
12 | Nitric oxide, superoxide, peroxide metabolism | 6 | 0.009 | 0.52 | 1 | 1.93 | 2.1 | 1.5% | Increased |
13 | Cardiolipin metabolism | 12 | 0.018 | 1.04 | 1 | 0.97 | 2.0 | 1.4% | Decreased |
14 | Bile salt metabolism | 8 | 0.012 | 0.69 | 1 | 1.45 | 1.8 | 1.3% | Increased |
15 | Branch chain amino acid metabolism | 13 | 0.019 | 1.12 | 1 | 0.89 | 1.7 | 1.2% | Increased |
16 | Isoleucine, valine, threonine, or methionine metabolism | 4 | 0.006 | 0.35 | 1 | 2.90 | 1.7 | 1.2% | Increased |
17 | Pyrimidine metabolism | 31 | 0.051 | 2.68 | 1 | 0.37 | 1.6 | 1.1% | Decreased |
18 | Krebs cycle | 17 | 0.025 | 1.47 | 1 | 0.68 | 1.6 | 1.1% | Increased |
19 | Vitamin B6 (pyridoxine) metabolism | 5 | 0.007 | 0.43 | 1 | 2.32 | 1.5 | 1.1% | Increased |
20 | Pentose phosphate, gluconate metabolism | 11 | 0.016 | 0.95 | 1 | 1.05 | 1.5 | 1.1% | Increased |
 | 20 of 60 pathways dysregulated | 532 (0.79 x 673) | 79% (532/673) | 46 (0.79 x 58) | 58 |  | 136.0 | 100% | 33/58 Increased |